Avidity Biosciences Inc Stock
Avidity Biosciences Inc Stock price
Key metrics
| Market capitalization | $3.59b |
| Enterprise Value | $2.01b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 198.75 |
| P/S ratio (TTM) P/S ratio | 354.98 |
| P/B ratio (TTM) P/B ratio | 2.38 |
| Revenue growth (TTM) Revenue growth | -0.19% |
| Revenue (TTM) Revenue | $10.12m |
Is Avidity Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Avidity Biosciences Inc Stock Analysis
Analyst Opinions
11 Analysts have issued a Avidity Biosciences Inc forecast:
Analyst Opinions
11 Analysts have issued a Avidity Biosciences Inc forecast:
Financial data from Avidity Biosciences Inc
| Sep '24 |
+/-
%
|
||
| Revenue | 10 10 |
0%
0%
|
|
| Gross Profit | 7.46 7.46 |
22%
22%
|
|
| EBITDA | -322 -322 |
48%
48%
|
EBIT (Operating Income) EBIT | -325 -325 |
46%
46%
|
| Net Profit | -280 -280 |
39%
39%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Avidity Biosciences Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avidity Biosciences Inc Stock News
Company Profile
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.
| Head office | United States |
| CEO | Sarah Boyce |
| Employees | 253 |
| Founded | 2012 |
| Website | www.aviditybiosciences.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
